|
rs137852581
|
|
Malignant neoplasm of prostate
|
|
0.720 |
GeneticVariation
|
BEFREE |
SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant.
|
9092797 |
1997 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles.
|
10501358 |
1999 |
|
rs523349
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data do not support a moderate to large effect of the SRD5A2 V89L polymorphism on plasma AAG levels or CaP risk in this predominantly Caucasian cohort, although a small effect cannot be completely excluded.
|
10606227 |
1999 |
|
rs137852593
|
|
Malignant neoplasm of prostate
|
|
0.740 |
GeneticVariation
|
BEFREE |
The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients.
|
11103816 |
2000 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that the A49T mutation may influence the pathological characteristics of prostate cancers and, thus, may affect the prognosis of these patients.
|
10749132 |
2000 |
|
rs1056836
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Because CYP1B1 is involved in hormone and carcinogen metabolism, and given the disparate rates of prostate cancer among ethnic groups, we also evaluated the association of the CYP1B1 Leu432Val polymorphism with prostate cancer risk in a pilot case-control study.
|
11221602 |
2000 |
|
rs1902023
|
|
Malignant neoplasm of prostate
|
|
0.070 |
GeneticVariation
|
BEFREE |
An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer.
|
11129427 |
2000 |
|
rs149709822
|
|
Malignant neoplasm of prostate
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our results suggest that the A49T mutation may influence the pathological characteristics of prostate cancers and, thus, may affect the prognosis of these patients.
|
10749132 |
2000 |
|
rs1801155
|
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Therefore, our finding, that patients under age 70 carrying the I1307K allele are significantly thinner than those carrying the wild type allele, suggests that the APC I1307K allele is also a prostate cancer risk factor.
|
11106824 |
2000 |
|
rs1463038513
|
|
Malignant neoplasm of prostate
|
|
0.030 |
GeneticVariation
|
BEFREE |
Therefore, our finding, that patients under age 70 carrying the I1307K allele are significantly thinner than those carrying the wild type allele, suggests that the APC I1307K allele is also a prostate cancer risk factor.
|
11106824 |
2000 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population.
|
11355945 |
2001 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
To provide etiological clues, we evaluated the relationships of four polymorphic markers in the SRD5A2 gene, specifically, A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA)n dinucleotide repeat, with prostate cancer risk in a population-based case-control study in China, a population with the lowest reported prostate cancer incidence rate in the world.
|
11588134 |
2001 |
|
rs523349
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The CYP17 MspA1 I polymorphism has been associated with increased prostate cancer risk, and the SRD5A2 V89L polymorphism has been associated with low A-diol-g in Asian men, a serum marker of 5alpha-reductase activity.
|
11303586 |
2001 |
|
rs523349
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
To provide etiological clues, we evaluated the relationships of four polymorphic markers in the SRD5A2 gene, specifically, A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA)n dinucleotide repeat, with prostate cancer risk in a population-based case-control study in China, a population with the lowest reported prostate cancer incidence rate in the world.
|
11588134 |
2001 |
|
rs523349
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also found no evidence of a gene-gene interaction between CYP17 and SRD5A2 V89L polymorphisms on prostate cancer risk or endogenous steroid hormone levels.
|
11440959 |
2001 |
|
rs5030739
|
|
Malignant neoplasm of prostate
|
|
0.090 |
GeneticVariation
|
BEFREE |
The prevalence of the HPC2 Ala541Thr allele was similar in men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) (P = .83).
|
11254449 |
2001 |
|
rs9332964
|
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
To provide etiological clues, we evaluated the relationships of four polymorphic markers in the SRD5A2 gene, specifically, A49T (a substitution of threonine for alanine at codon 49), V89L (a substitution of leucine for valine at codon 89), R227Q (a substitution of glutamine for arginine at codon 227), and a (TA)n dinucleotide repeat, with prostate cancer risk in a population-based case-control study in China, a population with the lowest reported prostate cancer incidence rate in the world.
|
11588134 |
2001 |
|
rs1293441395
|
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
The prevalence of the HPC2 Ala541Thr allele was similar in men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) (P = .83).
|
11254449 |
2001 |
|
rs864622007
|
|
Malignant neoplasm of prostate
|
|
0.830 |
GeneticVariation
|
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs864622007
|
|
Malignant neoplasm of prostate
|
|
0.830 |
GeneticVariation
|
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs137852578
|
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
rs137852578
|
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
|
rs9282858
|
|
Malignant neoplasm of prostate
|
|
0.100 |
GeneticVariation
|
BEFREE |
The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk.
|
12042668 |
2002 |